New chemo duo aims to shrink abdominal tumors in pancreatic cancer
NCT ID NCT07030283
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 33 times
Summary
This early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemo (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will receive the combination every two weeks and be monitored for side effects, tumor response, and survival. If the cancer shrinks enough, some may become eligible for surgery to remove it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.